Ireland-based Perrigo Company plc (NYSE, TASE: PRGO) announced yesterday that it has named James Dillard as its new executive vice president and chief scientific officer.
In this new role, Dillard will be responsible for providing global oversight and coordination to Perrigo's Research & Development, Quality, Regulatory and Innovation efforts. He will report to president and chief executive officer, Murray S Kessler.
Dillard is joining Perrigo from Altria Group Inc, where he served as senior vice president, Research, Development and Sciences and chief innovation officer. He also led the manufacturing, science and technology functions for United States Smokeless Tobacco Company, part of the Altria organisation. Between 1987 and 2001, he worked for the FDA, where he last served as director of the Division of Cardiovascular and Respiratory Devices. During his 14 years at the FDA, he held various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA